Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Seer Inc (Nasdaq: SEER) announced its participation in the 21st Annual US HUPO Conference in Philadelphia from February 22-26, 2025. The company will showcase new findings and host a seminar featuring groundbreaking research in cancer therapy using their Proteograph™ Product Suite.
The seminar will highlight Dr. Jinjun Shi's research from Brigham and Women's Hospital and Harvard Medical School, focusing on a novel co-delivery therapeutic platform that simultaneously targets cancer vulnerabilities using siRNA while activating tumor suppressors with mRNA. The study specifically addresses prostate cancer, the second leading cause of cancer death among men in the US.
Seer recently introduced a new workflow for deep cellular proteome analysis, adding to their existing 10+ Proteograph protocols for various sample types. The conference will also feature presentations from Seer and collaborators on tissue biology, cardiometabolic dysfunction biomarkers, and mass spectrometry proteomics throughput advancements.
Seer Inc (Nasdaq: SEER) ha annunciato la sua partecipazione alla 21ª Conferenza Annuale US HUPO a Filadelfia dal 22 al 26 febbraio 2025. L'azienda presenterà nuove scoperte e ospiterà un seminario incentrato su ricerche rivoluzionarie nella terapia del cancro utilizzando il loro Proteograph™ Product Suite.
Il seminario metterà in evidenza la ricerca del Dr. Jinjun Shi del Brigham and Women's Hospital e della Harvard Medical School, focalizzandosi su una nuova piattaforma terapeutica di co-somministrazione che mira simultaneamente alle vulnerabilità del cancro utilizzando siRNA mentre attiva i soppressori tumorali con mRNA. Lo studio affronta specificamente il cancro alla prostata, la seconda causa principale di morte per cancro tra gli uomini negli Stati Uniti.
Seer ha recentemente introdotto un nuovo flusso di lavoro per l'analisi profonda del proteoma cellulare, aggiungendo ai suoi oltre 10 protocolli Proteograph esistenti per vari tipi di campioni. La conferenza presenterà anche presentazioni da parte di Seer e collaboratori su biologia dei tessuti, biomarcatori di disfunzione cardiometabolica e avanzamenti nel throughput della proteomica di spettrometria di massa.
Seer Inc (Nasdaq: SEER) anunció su participación en la 21ª Conferencia Anual de US HUPO en Filadelfia del 22 al 26 de febrero de 2025. La empresa presentará nuevos hallazgos y organizará un seminario que contará con investigaciones innovadoras en terapia del cáncer utilizando su Proteograph™ Product Suite.
El seminario destacará la investigación del Dr. Jinjun Shi del Brigham and Women's Hospital y la Harvard Medical School, centrándose en una nueva plataforma terapéutica de co-administración que apunta simultáneamente a las vulnerabilidades del cáncer utilizando siRNA mientras activa los supresores tumorales con mRNA. El estudio aborda específicamente el cáncer de próstata, la segunda causa principal de muerte por cáncer entre los hombres en los EE. UU.
Seer ha introducido recientemente un nuevo flujo de trabajo para el análisis profundo del proteoma celular, sumando a sus más de 10 protocolos Proteograph existentes para varios tipos de muestras. La conferencia también contará con presentaciones de Seer y colaboradores sobre biología de tejidos, biomarcadores de disfunción cardiometabólica y avances en el rendimiento de la proteómica de espectrometría de masas.
Seer Inc (Nasdaq: SEER)은 2025년 2월 22일부터 26일까지 필라델피아에서 열리는 제21회 미국 HUPO 컨퍼런스에 참가한다고 발표했습니다. 이 회사는 새로운 발견을 선보이고, Proteograph™ Product Suite를 사용한 암 치료의 획기적인 연구를 다루는 세미나를 주최할 예정입니다.
세미나에서는 브리검 여성 병원과 하버드 의대의 진준 시 박사의 연구를 강조하며, siRNA를 사용하여 암의 취약점을 동시에 겨냥하고 mRNA로 종양 억제제를 활성화하는 새로운 공동 전달 치료 플랫폼에 초점을 맞춥니다. 이 연구는 미국에서 남성의 암 사망 원인 중 두 번째인 전립선 암을 구체적으로 다룹니다.
Seer는 최근 다양한 샘플 유형에 대한 기존 10개 이상의 Proteograph 프로토콜을 추가하여 심층 세포 단백질체 분석을 위한 새로운 작업 흐름을 도입했습니다. 이 컨퍼런스에서는 조직 생물학, 심혈관 대사 기능 장애 바이오마커 및 질량 분석 단백질체학의 처리량 향상에 대한 Seer 및 협력자들의 발표도 있을 예정입니다.
Seer Inc (Nasdaq: SEER) a annoncé sa participation à la 21ème Conférence Annuelle US HUPO qui se tiendra à Philadelphie du 22 au 26 février 2025. L'entreprise présentera de nouvelles découvertes et animera un séminaire mettant en avant des recherches révolutionnaires sur la thérapie du cancer en utilisant leur Proteograph™ Product Suite.
Le séminaire mettra en lumière les recherches du Dr. Jinjun Shi de l'Hôpital Brigham and Women's et de la Harvard Medical School, se concentrant sur une nouvelle plateforme thérapeutique de co-administration qui cible simultanément les vulnérabilités cancéreuses avec de l'ARNsi tout en activant les suppresseurs tumoraux avec de l'ARNm. L'étude aborde spécifiquement le cancer de la prostate, la deuxième cause de décès par cancer chez les hommes aux États-Unis.
Seer a récemment introduit un nouveau flux de travail pour l'analyse approfondie du protéome cellulaire, ajoutant à ses plus de 10 protocoles Proteograph existants pour divers types d'échantillons. La conférence présentera également des présentations de Seer et de ses collaborateurs sur la biologie des tissus, les biomarqueurs de dysfonctionnement cardiométabolique et les avancées dans le débit de la protéomique par spectrométrie de masse.
Seer Inc (Nasdaq: SEER) gab seine Teilnahme an der 21. Jahrestagung der US HUPO-Konferenz in Philadelphia vom 22. bis 26. Februar 2025 bekannt. Das Unternehmen wird neue Erkenntnisse präsentieren und ein Seminar veranstalten, das bahnbrechende Forschungen zur Krebsbehandlung mit ihrem Proteograph™ Product Suite vorstellen wird.
Das Seminar wird die Forschung von Dr. Jinjun Shi vom Brigham and Women's Hospital und der Harvard Medical School hervorheben, die sich auf eine neuartige Co-Delivery-Therapieplattform konzentriert, die gleichzeitig Krebsanfälligkeiten mit siRNA angreift und Tumorsuppressoren mit mRNA aktiviert. Die Studie befasst sich speziell mit Prostatakrebs, der zweithäufigsten Todesursache durch Krebs bei Männern in den USA.
Seer hat kürzlich einen neuen Arbeitsablauf für die tiefgehende Analyse des zellulären Proteoms eingeführt, der zu seinen bestehenden über 10 Proteograph-Protokollen für verschiedene Probenarten hinzugefügt wird. Die Konferenz wird auch Präsentationen von Seer und Partnern zu Gewebebiologie, Biomarkern für kardiometabolische Dysfunktion und Fortschritten bei der Durchsatzanalyse der Massenspektrometrie-Proteomik umfassen.
- Introduction of new workflow for deep cellular proteome analysis
- Expansion of Proteograph protocols to 10+ sample types
- Collaboration with prominent research institutions
- None.
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer’s Proteograph™ Product Suite
REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025. As a US HUPO Conference sponsor, Seer will host a seminar highlighting novel advances in scalable deep cellular proteomics using Seer’s Proteograph™ Product Suite. The seminar will feature a case study detailing a groundbreaking new co-delivery therapeutic platform for targeting cancer vulnerabilities with siRNA and mRNA therapeutics. The first-of-its-kind study describes the simultaneous inactivation of tumorigenic drivers using siRNA while activating lost tumor suppressors using mRNA and establishes a new core strategy for treatment of a broad range of cancers. Studying the cellular proteomic changes in response to these therapies yields critical biological insights that can drive further improvements in our ability to treat cancer.
Additional presentations from Seer and collaborators will highlight the Proteograph Product Suite’s role in deep proteomic studies to understand tissue biology, uncover biomarkers for cardiometabolic dysfunction, enable advancements in mass spectrometry proteomics throughput, and leverage model organisms to advance human health.
“This year’s US HUPO Conference represents the latest in a string of recent high-profile scientific meetings where leading research institutions will display new breakthroughs enabled by Seer’s technology,” said Asim Siddiqui, Senior Vice President & Scientific Fellow at Seer. “Partnering with prominent cancer researchers like Dr. Shi demonstrates Seer’s commitment to provide deep, unbiased proteomic insights that promise to accelerate advancements in precision cancer treatments.”
Dr. Shi’s presentation accompanies Seer’s introduction earlier this year of a new workflow that allows Proteograph users to conduct deep cellular proteome analysis using the company’s existing assay and instrument. This new capability adds to a growing list of 10+ Proteograph protocols available to conduct proteomic analysis on a diverse list of sample types, including non-human plasma/serum, conditioned media, cerebrospinal fluid (CSF), and dried blood spots.
Seer, Inc. Sponsored Seminar at the US HUPO 2025 Annual Conference:
Title: Transforming Cancer Research with Deep Cellular Proteomics
Presenter: Jinjun Shi, PhD, Associate Professor of Anesthesia, Brigham and Women's Hospital and Harvard Medical School
Date & Time: Tuesday, February 25, 7:15 a.m. to 8:15 a.m.
In this sponsored seminar, Dr. Shi will present novel findings from a first-of-its-kind RNA co-delivery study targeting both a tumor suppressor gene and a pro-tumorigenic transcription factor using Seer's Proteograph Product Suite. Dr. Shi’s seminar will discuss insights using deep proteomic profiling to evaluate cellular proteomic response, specifically in prostate cancer, the second leading cause of cancer death among men in the United States.
Highlights from Seer and Collaborators Presenting at the US HUPO 2025 Annual Conference:
1. Seer
- Title: Deep Profiling of Tissue Samples with a Scalable and Automated Multi-nanoparticle Based Proteomics Workflow (Oral Presentation)
- Presenting Author: Xiaoyan Zhao
- Date & Time: Tuesday, February 25, 1:40 p.m.
2. MaineHealth Institute for Research
- Title: Multi-omic Analysis Identifies Modulations in Amino Acid and Fatty Acid Metabolism Associated with Cardiovascular Dysfunction in RAB27a Mutant Mice (Oral Presentation)
- Presenting Author: Calvin Vary
- Date & Time: Monday, February. 24, 9:15 a.m.
3. Panome Bio
- Title: Moving Beyond Coverage: Assessing the Quantitative Accuracy of Affinity and Mass Spec Based Approaches to High-Throughput Proteomics (Oral Presentation)
- Presenting Author: Tom Cohen
- Date & Time: Tuesday, February 25, 9:15 a.m.
About Seer, Inc.
Seer, Inc. is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
For more information, please visit Booth #25 at US HUPO 2025 or contact us at pr@seer.bio.
Media Contact:
Consort Partners
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
What new cancer research technology will Seer (SEER) present at US HUPO 2025?
How many Proteograph protocols does Seer (SEER) currently offer?
When and where will Seer (SEER) present at US HUPO 2025?
What new workflow capability did Seer (SEER) introduce in 2025?
